- (a) an S RNA segment, characterized in that the S RNA segment has a sequence having at least 97.8 % sequence identity to SEQ ID NO:4 or SEQ ID NO:8;
- (b) an M RNA segment, characterized in that the M RNA segment has a sequence having at least 82.2 % sequence identity to SEQ ID NO:5;
- (c) an L RNA segment, characterized in that the L RNA segment has a sequence having at least 93 % sequence identity to SEQ ID NO:6; or
- (d) combinations thereof.

39. A composition of matter obtainable by the method according to claim 26.

40. The composition according to claim 39, wherein the composition is an immunogenic composition.

41. The composition according to claim 39, wherein the composition is a vaccine.

42. ~~A method of generating an immune response to SBV in an animal comprising administering to said animal the~~ The immunogenic composition according to claim 1 for use in generating an immune response to SBV in an animal.

43. Use of the immunogenic composition according to claim 1 in the manufacture of a medicament for the treatment or prevention of ~~A method of treating or preventing~~ SBV in ~~an animal in need of said treatment comprising administering to said animal a therapeutically effective amount of the immunogenic composition according to claim 1~~.

44. Use of the immunogenic composition according to claim 1 in the manufacture of a medicament for the treatment or prevention of ~~A method of treating or preventing~~ viremia or malformations induced by SBV ~~comprising administering to said animal a therapeutically effective amount of the immunogenic composition according to claim 1~~.

45. ~~A method for inducing an immune response against SBV in a herd of animals comprising the step of administering the~~ The immunogenic composition according to claim 1 for use in inducing an immune response against SBV in a herd of animals ~~to such animals in need thereof~~.

46. Use of the immunogenic composition according to claim 1 in the manufacture of a medicament for the treatment or reduction of ~~A method for preventing or reducing~~ viremia or malformations induced by SBV in a herd of animals ~~comprising the step of administering the immunogenic composition according to claim 1 to such animals in need thereof~~.

47. Use of the immunogenic composition according to claim 1 in the manufacture of a medicament for the prevention or reduction of ~~A method for preventing or reducing the~~ transmission of SBV in a herd of animals ~~comprising the step of administering the immunogenic composition according to claim 1 to such animals in need thereof~~.

48. The ~~method~~ immunogenic composition according to claim 42, wherein the immunogenic composition is formulated for administration ~~administered~~ in a single dose or in two doses.

49. The ~~method~~ use according to claim 43 wherein the immunogenic composition is formulated for administration ~~administered~~ in a single dose or in two doses.

50. The use ~~method~~ according to claim 44, wherein the immunogenic composition is formulated for administration ~~administered~~ in a single dose or in two doses.

51. The immunogenic composition ~~method~~ according to claim 45, wherein the immunogenic composition is formulated for administration ~~administered~~ in a single dose or in two doses.

52. The use ~~method~~ according to claim 46 wherein the immunogenic composition is formulated for administration ~~administered~~ in a single dose or in two doses.

53. The use ~~method~~ according to claim 47, wherein the immunogenic composition is formulated for administration ~~administered~~ in a single dose or in two doses.